$7 Billion Onsemi-Synaptics Deal Signals a $6.4 Trillion M&A Cycle in 2026

The $7 billion all-stock acquisition of Synaptics by ON Semiconductor, announced this week, is more than a semiconductor sector headline. It is a signal of a broader inflection point in global dealmaking. Reuters flagged it as one of the largest live M&A announcements of the last 48 hours, alongside EDF’s divestiture of its US and Canada power-solutions unit to KKR and Safran’s exclusive talks to acquire Exail Technologies. Morgan Stanley now projects global mergers and acquisitions activity could reach a record $6.4 trillion in 2026. For CFOs, General Counsel, and M&A directors across Europe, the message is clear: dealmaking is accelerating, cross-border complexity is rising, and readiness — not opportunism — will separate winners from laggards.

AI, Physical AI, and the New Logic of Strategic Acquisitions

Onsemi’s acquisition of Synaptics — its largest to date — is explicitly framed around expansion into AI-enabled devices and “physical AI,” the convergence of artificial intelligence with sensors, robotics, and edge computing. This is consistent with a wider trend: strategic buyers are increasingly paying premiums not for revenue synergies alone, but for capability acquisition. Defence and dual-use technology is following the same logic, illustrated by Safran’s exclusive negotiations to acquire Exail Technologies, a French specialist in navigation, robotics, and marine systems.

For corporate finance teams, this shift has practical implications. Valuation models built purely on discounted cash flow and comparable transactions increasingly understate the strategic premium buyers are willing to pay for technology, IP, and talent that shorten time-to-capability by years. Boards evaluating acquisition targets — or defending against unsolicited approaches — should stress-test valuation assumptions against this capability-driven premium, particularly in AI, semiconductors, defence-adjacent technology, and advanced manufacturing.

Private Equity’s Return to European Healthcare and Industrial Assets

Reuters’ report of early takeover interest in Qiagen from EQT, Advent, and KKR underscores a resurgence of private equity competition for high-quality European healthcare and diagnostics assets. Combined with EDF’s sale of its US and Canada power-solutions business to KKR, these transactions point to two converging dynamics: sponsors deploying significant dry powder into defensible, cash-generative European businesses, and European corporates actively divesting non-core units to sharpen strategic focus and strengthen balance sheets.

This is a favourable environment for sell-side carve-outs, but it raises the bar on preparation. Private equity due diligence today extends well beyond financial statements — encompassing regulatory exposure (including EU foreign subsidies scrutiny and CFIUS-equivalent reviews for non-EU buyers), IT and data architecture separability, and standalone cost modelling. Corporates initiating divestitures should assume sponsor-grade diligence rigor and prepare carve-out financials, transition service agreements, and IP separation plans well in advance of launching a process.

Cross-Border Complexity: Regulation as a Deal Variable, Not an Afterthought

Every transaction referenced — Onsemi-Synaptics, EDF-KKR, Safran-Exail, and the Qiagen interest — involves cross-border capital, assets, or both. In Europe, this means deal teams must navigate the EU Foreign Subsidies Regulation, sector-specific foreign direct investment screening (notably acute for defence-adjacent assets like Exail), and merger control filings across multiple jurisdictions simultaneously. In the US, CFIUS review remains a live consideration for any foreign acquirer of sensitive technology.

With Morgan Stanley forecasting record 2026 volumes, regulatory bottlenecks are likely to intensify rather than ease. General Counsel should treat regulatory strategy as a workstream that begins at term sheet stage, not after signing. Deal timelines increasingly hinge on pre-clearance signalling, remedies packages, and jurisdictional sequencing — factors that can materially affect deal certainty and, ultimately, price.

Implications for Business Leaders

• CFOs and corporate finance teams should revisit valuation frameworks to account for capability-driven premiums in AI, defence, and healthcare technology sectors.
• General Counsel must embed multi-jurisdictional regulatory analysis — EU FSR, FDI screening, antitrust — into deal timelines from the outset, not as a closing condition afterthought.
• M&A Directors should prepare for competitive, sponsor-heavy processes on quality assets, requiring sharper due diligence and faster decision cycles.
• CTOs should prioritise post-merger integration planning for technology and data systems early, given the AI and capability focus of current dealflow.
• Boards should reassess portfolio composition now, anticipating that non-core divestitures will find a receptive, well-capitalised private equity and venture capital buyer universe through 2026.

Key Takeaway

The current wave of M&A — from Onsemi’s AI-driven acquisition to private equity’s return to European healthcare and industrial assets — confirms that 2026 will reward organisations that treat regulatory strategy, valuation discipline, and post-merger integration as integrated, board-level priorities rather than sequential deal-execution steps.